1002-046 (Study 3) Phase 3 Efficacy Study

1002-046 (Study 3) Phase 3 Efficacy Study

LDL-C Percent Change from Baseline at 12 weeks

Format

PNG

Source

Esperion Therapeutics, Inc.

Downloads